NTRC 0652-0
Alternative Names: NTRC-0652-0Latest Information Update: 03 Oct 2023
At a glance
- Originator NTRC Therapeutics
- Developer Crossfire Oncology
- Class Amides; Antineoplastics; Indoles; Small molecules
- Mechanism of Action Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Cytokine release syndrome
Highest Development Phases
- Preclinical Cholangiocarcinoma; Cytokine release syndrome
Most Recent Events
- 09 Jun 2023 Chemical structure information added
- 03 Jan 2023 NTRC 0652-0 is available for licensing as of 03 Jan 2023. https://www.ntrctx.com/ntrc-our-science/ (NTRC Therapeutics pipeline, January 2023)
- 03 Jan 2023 Preclinical trials in Cytokine release syndrome in Netherlands (unspecified route) prior to January 2023 (NTRC Therapeutics pipeline, January 2023)